C

Cencora

Distributes medicines and supports patient care

Treasury Manager

Full-TimeUpdated on 10/22/2026
No salary listed
Senior
Bachelor's
London, UK+1 moreMore locations: Woking, UK
In PersonBased from the London or Woking office.
Finance & BankingTreasury

About the job

Requirements
  • Strong knowledge of corporate Treasury operations, including cash and liquidity management, cash pooling, intercompany funding, payments, foreign exchange, and banking.
  • Strong understanding of Treasury controls, governance, and financial risk management principles.
  • Experience working with treasury management systems, preferably Kyriba, and global banking platforms.
  • Strong analytical and problem-solving skills with the ability to manage complex financial and operational information.
  • Ability to manage multiple priorities and operate effectively in a fast-paced, multinational environment.
  • Strong communication and stakeholder-management skills, with the ability to collaborate effectively across Treasury, Finance, Accounting, Tax, Legal, IT, banking partners, and other stakeholders.
  • Bachelor’s degree in Finance or Accounting and 7 years of progressive corporate Treasury experience, with significant hands-on experience in cash management and Treasury operations.
Responsibilities
  • Manage day-to-day Treasury operations of Cencora’s in-house bank (AB Finco), including cash positioning, liquidity, intercompany funding, payments, and settlements.
  • Oversee cash positions across participating entities and support efficient concentration and deployment of liquidity through the company’s cash pooling structures.
  • Manage intercompany funding activities, including loan administration, funding requirements, interest calculations, settlements, and coordination of related Treasury documentation.
  • Compile and analyze the short-term cash forecast process with local finance for global entities across Alliance Healthcare, World Courier, and PharmaLex businesses.
  • Monitor foreign exchange exposures and execute or coordinate foreign exchange transactions and hedging activities in accordance with established Treasury policies and risk parameters.
  • Manage Treasury payment and settlement activities, ensuring transactions are executed accurately, timely, and in accordance with established controls and approval requirements.
  • Serve as a key Treasury contact for UK businesses and banking partners, supporting day-to-day Treasury activities.
  • Enhance the effectiveness of the global cash pool by onboarding more participant entities.
  • Execute the transition plan for in-sourcing activities of the Treasury Center from FTI.
  • Collaborate with Tax, Accounting, and Legal to implement in-house banking and the multi-notional cash pool.
  • Work with banks to open cash pool bank accounts and regional accounts and migrate operational activities to the new structure.
  • Support the onboarding of entities into the in-house bank and cash pooling structures, coordinating Treasury requirements and documentation with relevant internal and external stakeholders.
  • Prepare and maintain Treasury reporting, support effective Treasury controls and governance, and provide Treasury information and support for internal and external audit requirements.
  • Support internal controls activities.
Desired Qualifications
  • Experience working across multiple legal entities, currencies, and jurisdictions is strongly preferred.
  • A professional Treasury or Finance qualification such as ACT, CTP, or equivalent is preferred.

About the company

Cencora buys and distributes medicines for pharmacies, hospitals and physician practices, while helping drug manufacturers bring treatments to patients. Its businesses combine wholesale supply networks with specialty distribution for complex therapies and services that support prescribing and patient access. Customers order medicines through its distribution systems, and its teams manage sourcing, storage and delivery alongside pharmacy operations and manufacturer support. It earns revenue from pharmaceutical sales and fees for logistics and healthcare services. The parent company was formed in 2001 through the merger that created AmerisourceBergen, adopted the Cencora name in 2023, and is headquartered in Conshohocken, Pennsylvania.

Company Size

10,001+

Company Stage

IPO

Headquarters

Conshohocken, Pennsylvania

Founded

2001

Get referred to Cencora

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Pharmacy contracts deepen customer ties: Cencora negotiates insurer agreements and handles administrative work through its managed-care networks.
  • Eligible US staff gain retirement support: Cencora counts student-loan payments toward its employer match, up to 4% of pay.
  • Drug demand expands sales: Cencora reported 5.1% quarterly revenue growth in August 2026, led by higher US volumes.

What critics are saying

  • Customer dependence concentrates risk: Walgreens and Boots supplied 25% of Cencora's fiscal 2025 revenue, reported in November 2025.
  • Legal liabilities tie up cash: Cencora's November 2025 filing recorded $4.3 billion in opioid settlements, payable over 13 years.
  • Warehouse work is physical: Cencora's day-shift associate listing requires repeated lifting up to 50 pounds and overtime availability.

What makes Cencora unique

  • Independent pharmacies get a shared brand: Cencora's Good Neighbor Pharmacy franchise supports their merchandising and store identity.
  • Specialty shipments use reusable packaging: Cencora's World Courier Cocoon containers combine passive temperature control with live location monitoring.
  • Medicines arrive ready for bedside checks: Cencora's American Health Packaging sells barcoded unit doses that support hospital scanning.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Paid Parental Leave
  • Adoption Assistance
  • Infertility Coverage
  • Family Planning Benefits
  • Behavioral Health Solutions
  • Professional Development Budget
  • Training Programs

Company News

Financial News
Oct 21st, 2026
Cencora to buy American Oncology Network in $2.4bn deal

Cencora agrees to buy American Oncology Network for $2.4bn enterprise value, but a stockholder rollover means it may land only 75% of the company.

Yahoo Finance
Oct 16th, 2026
Cencora stock: $332.8B revenue, 14.4% EPS growth and 50.2% ROIC

Cencora, the pharmaceutical distributor formerly known as AmerisourceBergen, has risen 6% to $341.69 per share over the past six months. The S&P 500 gained 9.7% in the same period. The New York Stock Exchange-listed company (NYSE:COR) connects drug manufacturers with healthcare providers and offers logistics, data analytics, and consulting services. It rebranded in 2023. Its revenue reached $332.8 billion over the past 12 months, giving it scale and bargaining power with suppliers. That matters in a low-margin, volume-driven business. Earnings per share grew at a 14.4% compound annual rate over five years, outpacing 10.2% annualised revenue growth. Its five-year average return on invested capital was 50.2%. The shares trade at 17.4 times forward earnings.

Associated Press
Sep 2nd, 2026
Cencora launches cell and gene therapy service to help health systems scale advanced treatment programmes

Cencora has launched Cell and Gene Therapy Enablement through its Accelerate Pharmacy Solutions division to help health systems develop and expand cell and gene therapy programmes. The service provides support across financial planning, operational readiness, and scalable growth to reduce care barriers and improve patient access to advanced therapies. More than 35 cell and gene therapies have received FDA approval, with over 1,700 clinical trials underway globally. However, only 4% of health system pharmacy leaders report being fully prepared to integrate these treatments, highlighting infrastructure gaps. The offering includes market assessments, readiness evaluations, governance design, and workflow planning. Cencora, ranked number 10 on the Fortune 500 with over $300 billion in annual revenue, already provides specialty pharmaceutical services across the therapy lifecycle.

Yahoo Finance
Aug 14th, 2026
Cencora beats Q2 profit estimates as specialty pharma platform drives growth

Cencora reported second-quarter revenue of $84.75 billion, slightly above analyst estimates of $84.43 billion, representing 5.1% year-on-year growth. Adjusted earnings per share came in at $4.48, beating consensus estimates of $4.35 by 3%. Management attributed the performance to strength in specialty pharmaceuticals, particularly through Management Services Organisations like OneOncology and RCA. CEO Robert Mauch highlighted the company's positioning in specialty care, stating, "Our specialty platform supports growth across the healthcare ecosystem." The company raised its full-year adjusted EPS guidance to $17.85 at the midpoint. Operating margin held steady at 1.3%, matching the same quarter last year. During the earnings call, analysts questioned management about biosimilar opportunities, specialty logistics competition, and potential policy risks from proposed ASP rule changes.

Yahoo Finance
Aug 12th, 2026
Cencora raises FY2026 guidance after Q3 EPS jumps 12%, buys back $1B in shares

Cencora reported strong third-quarter results for fiscal year 2026, driven by execution across its business units and investments in its specialty positioning. The pharmaceutical distributor achieved double-digit adjusted operating income growth and 12% earnings per share growth in the quarter. The company conducted $1 billion in opportunistic share repurchases during the period. Based on its performance and confidence in continued execution, Cencora raised its fiscal 2026 EPS guidance. President and CEO Robert Mauch credited the results to the company's team members and their commitment to providing solutions for customers. He highlighted the strength of Cencora's portfolio and its pharmaceutical-centric strategy as the company approaches the end of its fiscal year. The earnings call was held on 5 August 2026, with senior leadership including Mauch and CFO Eva Boratto participating.